TG 100801 Hydrochloride

CAS No. : 1018069-81-2

TG 100801 Hydrochloride,1018069-81-2
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000132
Synonyms:4-chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate hydrochloride
Molecular Formula:C33H31Cl2N5O3
Molecular Weight:616.54
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

Cat No:I000132
Cas No:1018069-81-2
Product-Name:TG 100801 Hydrochloride

TG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
IC50 value:
Target: Src familt kinase; VEGFR
TG 100801 is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD. The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies, and may have great utility in the treatment of diseases such as AMD.

[1]. Palanki MS, Akiyama H, Campochiaro P et al. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59.
[2]. Mousa, Shaker A.; Mousa, Shaymaa S. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs (2010), 24(3), 183-194.
[3]. Doukas, John; Mahesh, Sankaranarayana; Umeda, Naoyasu et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. Journal of Cellular Physiology (2008), 216(1), 29-37.
[4]. A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers.
[5]. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029-36.

Related Products
  • CAS No. :338992-53-3
    Product Name:

    Vandetanib trifluoroacetate

    Cat No: I003227 View details
  • CAS No. :1210945-69-9
    Product Name:


    Cat No: I000789 View details
  • CAS No. :343787-29-1
    Product Name:


    Cat No: I003251 View details
  • CAS No. :252916-29-3
    Product Name:

    SU 6668

    Cat No: I002859 View details